JOURNAL 3020


Journal of Chemical Metrology
VOLUME & ISSUE
Year: 2024 Issue: 1 January-June
PAGES
p.19 - 29
STATISTICS
Viewed 1230 times.
AUTHORS
  • Anchal Shukla
  • Usmangani K. Chhalotiya
  • Dimal Shah
  • Jinal Tandel
  • Hetaben Kachhiya
  • Mital Parmar
PDF OF ARTICLE

GRAPHICAL ABSTRACT


ABSTRACT


Dapagliflozin inhibits selective sodium–glucose co-transporter-2 and Linagliptin competitively and reversibly inhibits dipeptidyl peptidase-4 in fixed dose Combination (1:1) is used in the treatment of Type 2 Diabetes Mellitus. For estimation Dapagliflozin and Linagliptin in bulk and Tablet formulation, an accurate and precise method using RP-HPLC was developed and validated. In the method being discussed here was optimized using Hypersil C18 (250 × 4.6 mm, 5 µm) column as Stationary Phase, Mobile Phase being used is Acetonitrile: Water (90:10) adjusting pH 3 using Ammonium Acetate. The Flow Rate was adjusted to 1ml/min. Both Dapagliflozin and Linagliptin (1:1) sample was detected at analytical wavelength of 244nm using Photo diode array detector. The Linearity Range was between Concentration of 0.1µg/ml to 20µg/ml with correlation Coefficient of 0.995 and 0.999 for Dapagliflozin and Linagiliptin Respectively.

KEYWORDS
  • Diabetes Mellitus
  • dapagliflozin
  • linagliptin
  • RP-HPLC
  • method validation

SUPPORTING INFORMATION


Supporting Information
Download File 104-JCM-2401-3020-SI.pdf (338.14 KB)